PPP1R3F

Across TCGA pan-cancer cohorts, PPP1R3F Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PPP1R3F data layer compared with 18 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PPP1R3F Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PPP1R3F expression acts as an unfavorable survival marker.

BLCA, OV, and SARC are the cancer types where PPP1R3F Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.120	0.720	<.001	45	view →
OV	OS	Median	II,III,IV	0.416	0.694	.011	12	view →
SARC	OS	Median	All	0.109	0.839	<.001	9	view →
STAD	OS	Median	III,IV	0.217	0.635	.013	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.115	0.730	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PPP1R3F–BLCA (OS)

Open the BLCA breakdown →